Vanda Pharmaceuticals (VNDA) Shares are Up 1.44%

Vanda Pharmaceuticals (VNDA) : Traders are bullish on Vanda Pharmaceuticals (VNDA) as it has outperformed the S&P 500 by a wide margin of 25.67% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.93%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.44% in the last 1 week, and is up 25.5% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 17.46% and the 50-Day Moving Average is 28.19%.The 200 Day SMA reached 59.56%. Vanda Pharmaceuticals, Inc. is up 37.85% in the last 3-month period. Year-to-Date the stock performance stands at 67.02%.


Vanda Pharmaceuticals (NASDAQ:VNDA): After opening at $15.26, the stock dipped to an intraday low of $15.08 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $15.63 and the buying power remained strong till the end. The stock closed at $15.55 for the day, a gain of 1.70% for the day session. The total traded volume was 442,973. The stocks close on the previous trading day was $15.29.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Companys product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.